Search tips
Search criteria 


Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
Biologics. 2012; 6: 21–29.
Published online Jan 1, 2012. doi:  10.2147/BTT.S19811
PMCID: PMC3266863
Eribulin mesylate in the treatment of metastatic breast cancer
Sarika Jain and Tessa Cigler
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Correspondence: Tessa Cigler, Weill Cornell Medical College Iris, Cantor Breast Center, 425 East 61st Street, 8th floor, New York, NY 10065, USA, Tel +1 212 821 0736, Fax +1 212 821 0796, Email tec9002/at/
The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.
Keywords: eribulin, metastatic breast cancer, microtubule
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press